On the importance of synthetic organic chemistry in drug discovery: Reflections on the discovery of antidiabetic agent ertugliflozin

MedChemComm

Volumn 4, Issue 1, 2013, Pages 101-111

  Mascitti, Vincent ^a   Thuma, Benjamin A ^a   Smith, Aaron C ^a   Robinson, Ralph P ^a   Brandt, Thomas ^a   Kalgutkar, Amit S ^a   Maurer, Tristan S ^a   Samas, Brian ^a   Sharma, Raman ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIOXABICYCLO[3.2.1]OCTANE; ERTUGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG SYNTHESIS; MEDICINAL CHEMISTRY; ORGANIC CHEMISTRY; PRIORITY JOURNAL;

EID: 84871767519     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c2md20163a     Document Type: Article

References (51)

1. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discovery 2009 8 959 968
2. S. M. Paul D. S. Mytelka C. T. Dunwiddie C. C. Persinger B. H. Munos S. R. Lindborg A. L. Schacht How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discovery 2010 9 203 214
3. H. Wild D. Heimbach C. Huwe Editorial: the importance of chemistry for the future of the pharma industry Angew. Chem., Int. Ed. 2011 50 7452 7453
4. V. Mascitti V. Snieckus S. Haak Editorial: a new vista in SYNFACTS Synfacts 2012 8 I
5. F. Lovering J. Bikker C. Humblet Escape from Flatland: Increasing Saturation as an Approach to Improvinc Clinical Success J. Med. Chem. 2009 52 6752
6. A. Nadin C. Hattotuwagama I. Churcher Lead-oriented synthesis: a new opportunity for synthetic chemistry Angew. Chem., Int. Ed. 2012 51 1114
7. V. Mascitti T. S. Maurer R. P. Robinson J. Bian C. M. Boustany-Kari T. Brandt B. M. Collman A. S. Kalgutkar M. K. Klenotic M. T. Leininger A. Lowe R. J. Maguire V. M. Masterson Z. Miao E. Mukaiyama J. D. Patel J. C. Pettersen C. Préville B. Samas L. She Z. Sobol C. M. Steppan B. D. Stevens B. A. Thuma M. Tugnait D. Zeng T. Zhu Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors J. Med. Chem. 2011 54 2952 2960
8. V. Mascitti, Discovery of a New Class of SGLT2 Inhibitors. Abstract of Papers. 240th National ACS Meeting; Boston, MA, United States, Aug 22-26, 2010, American Chemical Society, Washington, D.C., 2010, MEDI-21
9. Y. Kanai W. S. Lee G. You D. Brown M. A. Hediger The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose J. Clin. Invest. 1994 93 397
10. M. F. Albertoni Borghese M. P. Majowicz Inhibitors of sodium/glucose cotransporter Drugs Future 2009 34 297
11. J. J. Neumiller J. R. Jr White R. K. Campbell Sodium-glucose co-transport inhibitors. Progress and therapeutic potential in type 2 diabetes mellitus Drugs 2010 70 377
12. E. C. Chao R. R. Henry SGLT2 inhibition-a novel strategy for diabetes treatment Nat. Rev. Drug Discovery 2010 9 551
13. S. Nair J. P. H. Wilding Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J. Clin. Endocrinol. Metab. 2010 95 34
14. R. A. DeFronzo From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 2009 58 773
15. International Diabetes Federation, Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 4th edn, 2009
16. J. R. L. Ehrenkranz N. G. Lewis C. R. Kahn J. Roth Phlorizin: a review Diabetes/Metab. Res. Rev. 2005 21 31
17. J. R. White Jr Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition Clin. Diabetes 2010 28 5
18. W. N. Washburn Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin. Ther. Pat. 2009 19 1485 1499
19. E. K. Hussey R. V. Clark D. M. Amin M. S. Kipnes R. L. O'Connor-Semmes E. C. O'Driscoll J. Leong S. C. Murray R. L. Dobbins D. Layko D. J. R. Nunez Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus J. Clin. Pharmacol. 2010 50 623
20. E. K. Hussey R. L. Dobbins R. R. Stoltz N. L. Stockman R. L. O'Connor-Semmes A. Kapur S. C. Murray D. Layko D. J. R. Nunez Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study J. Clin. Pharmacol. 2010 50 636
21. W. N. Washburn Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2 J. Med. Chem. 2009 52 1785
22. W. Meng B. A. Ellsworth A. A. Nirschl P. J. McCann M. Patel R. N. Girotra G. Wu P. M. Sher E. P. Morrison S. A. Biller R. Zahler P. P. Deshpande A. Pullockaran D. L. Hagan N. Morgan J. R. Taylor M. T. Obermeier W. G. Humphreys A. Khanna L. Discenza J. G. Robertson A. Wang S. Han J. R. Wetterau E. B. Janovitz O. P. Flint J. M. Whaley W. N. Washburn Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J. Med. Chem. 2008 51 1145 1149
23. P. P. Deshpande B. A. Ellsworth F. G. Buono A. Pullockaran J. Singh T. P. Kissick M.-H. Huang H. Lobinger T. Denzel R. H. Mueller Remarkable β-selectivity in the synthesis of β-1-C-arylglucosides: stereoselective reduction of acetyl-protected methyl 1-C-arylglucosides without acetoxy-group participation J. Org. Chem. 2007 72 9746 9749
24. W. N. Washburn Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents Expert Opin. Ther. Pat. 2012 22 483 494
25. See article related to first disclosure in: Chemical Engineering News, 2012, 90 (16), 42, See also
26. N. C. Goodwin, B. A. Harrison, S. Iimura, R. Mabon, Q. Song, W. Wu, J. Yan, H. Zhang and M. M. Zhao, Preparation of glycosyl sulfoxides as potential antidiabetic sodium glucose co-transporter 2 inhibitors, PCT Int. Appl. WO2009014970, 2009, Chem. Abstr., 2009, 150, 144780
27. N. C. Goodwin R. Mabon B. A. Harrison M. K. Shadoan Z. Y. Almstead Y. Xie J. Healy L. M. Buhring C. M. DaCosta J. Bardenhagen F. Mseeh Q. Liu A. Nouraldeen A. G. E. Wilson S. D. Kimball D. R. Powell D. B. Rawlins Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes J. Med. Chem. 2009 52 6201 6204
28. S. Nomura S. Sakamaki M. Hongu E. Kawanishi Y. Koga T. Sakamoto Y. Yamamoto K. Ueta H. Kimata K. Nakayama M. Tsuda-Tsukimoto Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus J. Med. Chem. 2010 53 6355 6360
29. M. Imamura, T. Murakami, R. Shiraki, K. Ikegai, T. Sugane, F. Iwasaki, E. Kurosaki, H. Tomiyama, A. Noda, K. Kitta and Y. Kobayashi, Preparation of C-glycoside derivatives and salts thereof as Na glucose co-transporter inhibitor, PCT Int. Appl. WO2004080990, 2004, Chem. Abstr., 2004, 141, 296242
30. D. Weber, S. Renner, T. Fiedler and S. Orlich, Method for the preparation of a crystalline form of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-((S)- tetrahydrofuran-3-yloxy)benzyl)benzene, PCT Int. Appl. WO2011039107, 2011, Chem. Abstr., 2011, 154, 444966
31. H. Kakinuma T. Oi Y. Hashimoto-Tsuchiya M. Arai Y. Kawakita Y. Fukasawa I. Iida N. Hagima H. Takeuchi Y. Chino J. Asami L. Okumura-Kitajima F. Io D. Yamamoto N. Miyata T. Takahashi S. Uchida K. Yamamoto (1S)-1,5-Anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment J. Med. Chem. 2010 53 3247 3261
32. M. Murakata, T. Ikeda, N. Kimura, A. Kawase, M. Nagase, K. Yamamoto, N. Takata and S. Yoshizaki, Crystal of spiroketal derivative, and process for production thereof, PCT Int. Appl. WO2009154276, 2009, Chem. Abstr., 2009, 152, 75342
33. T. Sato, Discovery of O-spiroketal C-arylglucosides as novel and selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, Abstracts of Papers, 240th National ACS Meeting, Boston, MA, Aug 22-26, 2010, American Chemical Society, Washington, DC, 2010, MEDI-202.
34. B. Lv Y. Feng J. Dong M. Xu B. Xu W. Zhang Z. Sheng A. Welihinda B. Seed Y. Chen Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors ChemMedChem 2010 5 827 831
35. A. S. Kalgutkar I. Gardner R. S. Obach C. L. Shaffer E. Callegari K. R. Henne A. E. Mutlib D. K. Dalvie J. S. Lee Y. Nakai J. P. O'Donnell J. Boer S. P. Harriman A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 2005 6 161 225
36. A. S. Kalgutkar J. R. Soglia Minimising the potential for metabolic activation in drug discovery Expert Opin. Drug Metab. Toxicol. 2005 1 91 142
37. In Vitro Mammalian Cell Micronucleus Test (MNvit), OECD Guideline for Testing of Chemicals No. 487, OECD, Paris, 2010, http://www.oecd.org/env/ testguidelines
38. W. Washburn and W. Meng, C-aryl glucoside SGLT2 inhibitors and method for the treatment of diabetes and related diseases, US Pat., US 7,589,193, 2009, Chem. Abstr., 2006, 144, 305154
39. R. P. Robinson V. Mascitti C. M. Boustany-Kari C. L. Carr P. M. Foley E. Kimoto M. T. Leininger A. Lowe M. K. Klenotic J. I. MacDonald R. J. Maguire V. M. Masterson T. S. Maurer Z. Miao J. D. Patel C. Préville M. R. Reese L. She C. M. Steppan B. A. Thuma T. Zhu C-Aryl glycoside inhibitors of SGLT2: exploration of sugar modifications including C-5 spirocyclization Bioorg. Med. Chem. Lett. 2010 20 1569 1572
40. For another independent report see: G. R. Bebernitz, M. G. Bock, D. Bhuniya, L. Datrange, S. E. Kurhade, P. V. Palle and D. S. Reddy, Preparation of glycoside derivative as antidiabetic agents, PCT Int. Appl. WO2011048148, 2011, Chem. Abstr., 2011, 154, 486619
41. V. Mascitti R. P. Robinson C. Préville B. A. Thuma C. L. Carr M. R. Reese R. J. Maguire M. T. Leininger A. Lowe C. M. Steppan Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors Tetrahedron Lett. 2010 51 1880 1883
42. R. Schaffer Branched-chain higher sugars. III. A 4-C-(hydroxymethy1)- pentose J. Am. Chem. Soc. 1959 81 5452 5454
43. P. Picard D. Leclercq J.-P. Bats J. Moulines An efficient one-pot synthesis of oxetanes from 1,3-diols Synthesis 1981 550 551
44. T. S. Maurer A. Ghosh N. Haddish-Berhane A. Sawant-Basak C. M. Boustany-Kari L. She M. T. Leininger T. Zhu M. Tugnait X. Yang E. Kimoto V. Mascitti R. P. Robinson Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology AAPS J. 2011 13 576 585
45. V. Mascitti and B. M. Collman, Preparation of dioxa-bicyclo[3.2.1]octane- 2,3,4-triol derivatives as antidiabetic agents, PCT Int. Appl. WO2010023594, 2010, Chem. Abstr., 2010, 152, 311862
46. A. S. Kalgutkar M. Tugnait T. Zhu E. Kimoto Z. Miao V. Mascitti X. Yang B. Tan R. L. Walsky J. Chupka B. Feng R. P. Robinson Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus Drug Metab. Dispos. 2011 39 1609 1619
47. S. Hanessian, The Total Synthesis of Natural Products: The Chiron Approach, Pergamon Press, Oxford, 1983
48. E. J. Corey, and X. M. Cheng, The Logic of Chemical Synthesis, Wiley, New York, 1989
49. V. Mascitti C. Préville Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor Org. Lett. 2010 12 2940 2943
50. G. Nucci, Presented at the 47th EASD Meeting, Lisbon, September 2011, (abstract A-11-1092-EASD)
51. N. B. Amin, Presented at the 71st ADA Meeting, San Diego, CA, June 2011 (abstract 0048-LB)